Nephrology Dialysis Transplantation最新文献

{"title":"On the fragility of outcome measures of two individual patient data analyses from randomized controlled trials on online haemodiafiltration.","authors":"Carlo Basile, Alessandro Mantovani, Yuri Battaglia","doi":"10.1093/ndt/gfaf085","DOIUrl":"10.1093/ndt/gfaf085","url":null,"abstract":"","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":"1806-1808"},"PeriodicalIF":5.6,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144039346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrence of CKD-associated pruritus after discontinuation of difelikefalin.","authors":"Rémi Brasme, Alexandre Candellier, Morgane Wetzstein, Maxime Schleef, Pablo Urena-Torres, Léa Moret, Céline Estournet, Vladimir Coliche, Amandine Darres, Angelo Testa, Nathalie Maisonneuve, Marie-Flore Hennino","doi":"10.1093/ndt/gfaf081","DOIUrl":"10.1093/ndt/gfaf081","url":null,"abstract":"","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":"1799-1801"},"PeriodicalIF":5.6,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143991168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A predicting tool for kidney function recovery after drug-induced acute interstitial nephritis.","authors":"Fernando Caravaca-Fontán, Marina Alonso-Riaño, Amir Shabaka, Javier Villacorta, Alberto de Lorenzo, Luis F Quintana, Eva Rodríguez, Liliana Gadola, María Ángeles Cobo, Aniana Oliet, Milagros Sierra-Carpio, Carmen Cobelo, Elena Iglesias, Alfredo Cordón, Manuel Praga, Gema Fernández-Juárez","doi":"10.1093/ndt/gfaf037","DOIUrl":"10.1093/ndt/gfaf037","url":null,"abstract":"<p><strong>Background: </strong>Drug-induced acute interstitial nephritis (DI-AIN) represents a common cause of acute kidney injury. Early withdrawal of the culprit drug and corticosteroid therapy remains the mainstay of treatment. This study aimed to develop and validate a predictive nomogram to assess the probability of recovery of kidney function at 6 months after treatment.</p><p><strong>Methods: </strong>A multicenter, retrospective, observational study was conducted in 13 nephrology departments. Patients with biopsy proven DI-AIN treated with corticosteroids between 1996 and 2023 were included. The dataset was randomly divided into training (n = 164) and validation (n = 60) sets. Least absolute shrinkage and selection operator regression was used to screen the main predictors of complete (creatinine increase <25% of the last value before DI-AIN) or no recovery of kidney function (serum creatinine ≥75% or need for dialysis).</p><p><strong>Results: </strong>The study group comprised 224 patients with DI-AIN: 51 (31%) in the training group and 19 (32%) in the validation set achieved complete recovery at 6 months. Conversely, 33 (20%) and 8 (13%) patients in the two sets showed no recovery at 6 months. Clinical characteristics were well balanced between training and validation sets. The selected variables were age (under/above 65 years), gender, degree of interstitial fibrosis and time to corticosteroid initiation (under/above 7 days). Based on a multivariable logistic regression model, a nomogram was developed. The area under the curve of the nomogram was 0.79 (95% confidence interval 0.71-0.88), indicating good discriminative power. Bootstrap self-sampling was performed 1000 times for validation of the model. A calibration plot revealed that the predicted outcomes aligned well with the observations. Decision curve analysis suggested that the model had clinical benefit.</p><p><strong>Conclusions: </strong>We developed and validated a nomogram to predict kidney recovery at 6 months in DI-AIN patients treated with corticosteroids. This tool helps clinicians estimate prognosis and optimize corticosteroid therapy's intensity and duration for better treatment outcomes.</p>","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":"1707-1716"},"PeriodicalIF":5.6,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalized disease recurrence modeling using iPSC-derived podocytes in patients with idiopathic nephrotic syndrome.","authors":"Bartholomeus T van den Berge, Martijn van den Broek, Gianluca Di Giovanni, Hanna Debiec, Sharon Gloudemans, Quinty Leusink, Dirk den Braanker, Jack F M Wetzels, Pierre Ronco, Bart Smeets, Jitske Jansen, Rutger J Maas","doi":"10.1093/ndt/gfaf045","DOIUrl":"10.1093/ndt/gfaf045","url":null,"abstract":"<p><strong>Background: </strong>Primary focal segmental glomerulosclerosis (FSGS) is characterized by podocyte injury and treatment-resistant nephrotic syndrome. Recurrence of the original disease after kidney transplantation (rFSGS) occurs in 10%-50% of patients. Unidentified circulating permeability factors (CPF) are likely involved in FSGS pathogenesis. We hypothesized that donor podocyte susceptibility to CPF is also relevant. We developed a personalized model for (r)FSGS using induced pluripotent stem cell (iPSC)-derived podocytes from patients and kidney donors.</p><p><strong>Methods: </strong>Five patients and their respective living kidney donors were included. Three patients had developed rFSGS, and two patients manifested no symptoms of rFSGS. One patient (P5) had heterozygous mutations in NPHS2. Peripheral blood mononuclear cells were reprogrammed to iPSC, and differentiated to podocytes. iPSC-derived podocytes from either patients or donors were exposed to presumed CPF-containing plasma/serum of corresponding patients. Three assays to detect podocyte injury were performed: (i) reactive oxygen species formation, (ii) cellular granularity induction, and (iii) quantitative assessment of F-actin redistribution (FAR), a new quantitative method. Crossmatch experiments with donor iPSC-derived podocytes and patients samples assessed individual susceptibility to CPF-induced injury.</p><p><strong>Results: </strong>Successful podocyte differentiation was confirmed by morphology and protein expression. Only FAR differentiated consistently between patient and healthy donor samples. All pre-transplant patient samples except P5 caused significant FAR in corresponding patient podocytes. Significant FAR was observed in donor podocytes exposed to corresponding patient samples in the setting of rFSGS, and not in donor podocytes exposed to samples of patients who did not develop rFSGS. Effects of FSGS patient samples on non-corresponding donor podocytes were variable.</p><p><strong>Conclusions: </strong>In vitro assays using iPSC-derived donor podocytes may allow individualized assessment of rFSGS. Prospective studies in a larger cohort are required to validate our findings.</p>","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":"1736-1745"},"PeriodicalIF":5.6,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12451694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143557558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The long-term effect of tolvaptan treatment on kidney function and volume in patients with ADPKD.","authors":"Paul Geertsema, Thomas Bais, Vera Kuiken, Martine G E Knol, Niek F Casteleijn, Priya Vart, Esther Meijer, Ron T Gansevoort","doi":"10.1093/ndt/gfaf048","DOIUrl":"10.1093/ndt/gfaf048","url":null,"abstract":"<p><strong>Background and hypothesis: </strong>The only therapy to ameliorate disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD) is tolvaptan, a vasopressin V2 receptor antagonist. Real-life data on long-term tolvaptan treatment are sparse and limited by restricted follow-up, small patient groups or lack of a control group. We studied the long-term effect of tolvaptan on kidney function and kidney growth in real-life patients and controls. Moreover, we investigated determinants of long-term treatment efficacy.</p><p><strong>Methods: </strong>Data from the prospective DIPAK cohort and retrospective OBSERVA cohort were pooled. estimated glomerular filtration rate (eGFR) was measured at least yearly and total kidney volume (TKV) at least every 3 years. Treatment effects from the start to 6 weeks after initiation of tolvaptan were analyzed as \"acute slope.\" After this, endpoints were analyzed as \"chronic slope.\" As a control group, we included all patients who were not treated with tolvaptan, assessing change in endpoints before and during theoretical treatment (based on the average time of tolvaptan initiation in tolvaptan-treated patients).</p><p><strong>Results: </strong>A total of 615 patients (48 ± 12 years, 58.2% female) were included in the full analysis, of which 105 (17.1%) were treated with tolvaptan. The average duration of treatment was 6.1 ± 4.7 years (range 0.8 to 15.9). After matching, two groups of 92 patients remained for matched analysis. In this analysis, tolvaptan reduced eGFR decline during chronic slope by 14.0% (-4.36 to -3.75 mL/min/1.73 m2/year, P = .03), versus a decrease of 1.0% (-4.16 to -4.12 mL/min/1.73 m2/year, P = .9) in the control group. Long-term TKV growth did not significantly change during tolvaptan treatment (5.05 to 5.59%/year P = .6). In subgroup analyses, patients with a higher mean osmolar intake had a larger treatment effect of tolvaptan.</p><p><strong>Conclusion: </strong>In this study, with real-life patient data, long-term follow-up and a well-matched control group, we found that tolvaptan attenuated long-term kidney function decline but seemed not to influence kidney growth.</p>","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":"1764-1774"},"PeriodicalIF":5.6,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12451683/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re-biopsy may guide novel immunosuppressive therapy in long-standing IgA nephropathy.","authors":"Christodoulos Keskinis, Panagiotis Pateinakis, Maria Stangou","doi":"10.1093/ndt/gfaf039","DOIUrl":"10.1093/ndt/gfaf039","url":null,"abstract":"","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":"1639-1642"},"PeriodicalIF":5.6,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kidney expert consultation and the outcomes of in hospital acute kidney injury.","authors":"Turgay Saritas, Vincenzo Cantaluppi, Ana Sanz Bartolome, Stanislas Faguer, Joana Gameiro, Jose Antonio Lopes, Jolanta Malyszko, Marlies Ostermann, Nicholas M Selby, Sophie de Seigneux","doi":"10.1093/ndt/gfaf043","DOIUrl":"10.1093/ndt/gfaf043","url":null,"abstract":"","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":"1643-1645"},"PeriodicalIF":5.6,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143557505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 infection and the progression of kidney disease in British Columbia, Canada.","authors":"Mohammad Atiquzzaman, Lee Er, Ognjenka Djurdjev, Yuyan Zheng, Michelle M Y Wong, Peter C Birks, Micheli U Bevilacqua, Kevin Yau, Michelle A Hladunewich, Matthew J Oliver, Adeera Levin","doi":"10.1093/ndt/gfaf040","DOIUrl":"10.1093/ndt/gfaf040","url":null,"abstract":"<p><strong>Background: </strong>We investigated the long-term effect of COVID-19 on estimated glomerular filtration rate (eGFR) trajectory and the association with progression to kidney failure in patients with CKD.</p><p><strong>Methods: </strong>Patients living with non-dialysis-dependent CKD from British Columbia, Canada infected with COVID-19 (cases) were matched 1:2 to non-COVID-19-infected controls on variables including pre-COVID-19 annual rate of eGFR decline. Patients were followed from 90 days from the date of COVID-19 diagnosis. The Cox proportional hazard model was used for the primary outcome of kidney failure, defined as a composite of eGFR reaching <15 ml/min/1.73 m2, initiation of maintenance dialysis or kidney transplantation. A linear mixed regression model was used to calculate the annual rate of change in eGFR.</p><p><strong>Results: </strong>The study included 802 patients: 268 cases and 534 controls. The median age was 70 years and 54% were male. Over ≈3 years of follow-up, the risk of developing kidney failure did not differ significantly between cases and controls. The annual rate of eGFR decline was 2.05 ml/min/1.73 m2 among cases versus 1.35 ml/min/1.73 m2 among controls, representing a rate difference of 0.71 ml/min/1.73 m2 (P = .02).</p><p><strong>Conclusion: </strong>In patients with non-dialysis-dependent CKD who survived at least 90 days without requiring dialysis, COVID-19 was not associated with an increased long-term risk of kidney failure over 3 years but was associated with a greater annual decline in eGFR. Future research with longer follow-up is required to examine if this difference persists and leads to increased risk for kidney failure.</p>","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":"1717-1726"},"PeriodicalIF":5.6,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of different heparin-free dialysis methods.","authors":"Marie Quennepoix, Laetitia Koppe, Alban Bevier, Christophe Barba, Maxime Espi, Cécile Barnel, Denis Fouque, Etienne Novel-Catin","doi":"10.1093/ndt/gfaf082","DOIUrl":"10.1093/ndt/gfaf082","url":null,"abstract":"","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":"1802-1805"},"PeriodicalIF":5.6,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144008982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Very low SBP targets and the boom-and-bust cycle of benefit and adverse kidney events.","authors":"Beatriz Fernandez-Fernandez, Jose M Valdivielso, Shanmugakumar Chinnappa, Pantelis Sarafidis, Alberto Ortiz","doi":"10.1093/ndt/gfaf053","DOIUrl":"10.1093/ndt/gfaf053","url":null,"abstract":"","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":"1646-1649"},"PeriodicalIF":5.6,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12451685/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143575913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}